Tamoxifen reduces the absolute risk of breast cancer by a few percentage points, and the overall absolute risk following an LCIS diagnosis remains relatively low.

“so I know their data ply well I don't don't have any other commercial conflicts of interest but I do work with the NSA so they did a study called the P1 study which was a prevention study the goal of this study which was published over 20 years ago was to see if Tom oopen could lower the risk of breast cancer diagnosis in women who were at intermediate to moderate risk of developing breast cancer and so in that trial they included a lot of women who had lobular carcinoma in saitu and those women were at greater risk of developing breast cancer so that risk just to be quantitative so I'm looking this up as I speak to you was there was a rate of 13 per per th000 women 13 per thousand women per year and tomox havean cut that in half down to about five or six per thousand women per year”

“so this study took women who were at high risk who had been diagnosed or had not yet been diagnosed with breast cancer so they had a higher RIS risk was family history yeah they had higher risk because of family history or because of atypical hyperplasia or other there was a whole algorithm that went into the risk assessment so wom higher risk these women took tamoxifen for how long five years versus a placebo”